TRCT
BIAF icon

Tower Research Capital (TRC)’s bioAffinity Technologies BIAF Stock Holding History

Tower Research Capital (TRC)’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.26K Buy
6,482
+4,419
+214% +$9.03K ﹤0.01% 4290
2026
Q1 		$7.9K Sell
2,063
-1,841
-47% -$2.97K ﹤0.01% 3997
2025
Q4 		$4.61K Buy
3,904
+1,405
+56% +$2.8K ﹤0.01% 4200
2025
Q3 		$7.4K Buy
2,499
+2,395
+2,303% +$19K ﹤0.01% 4100
2025
Q2 		$898 Sell
104
-1
-1% -$11 ﹤0.01% 4918
2025
Q1 		$817 Sell
105
-106
-50% -$1.94K ﹤0.01% 4824
2024
Q4 		$5.76K Buy
211
+141
+201% +$5.67K ﹤0.01% 4246
2024
Q3 		$4.34K Sell
70
-84
-55% -$5.03K ﹤0.01% 4582
2024
Q2 		$9.97K Buy
154
+42
+38% +$2.91K ﹤0.01% 4191
2024
Q1 		$6.76K Buy
112
+13
+13% +$678 ﹤0.01% 4320
2023
Q4 		$4.36K Sell
99
-36
-27% -$1.54K ﹤0.01% 4964
2023
Q3 		$4.71K Buy
135
+89
+193% +$4.52K ﹤0.01% 4829
2023
Q2 		$2.53K Buy
+46
New +$2.54K ﹤0.01% 5189
2022
Q4 		– Sell
-1
Closed – – 5896
2022
Q3 		$0 Buy
+1
New +$126 ﹤0.01% 6063

Other funds holding BIAF

JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s BIAF Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its bioAffinity Technologies (BIAF) stake by 214% in Q2 2026, buying an estimated $9.03K and bringing the position to 6,482 shares worth $5.26K. The position accounts for ﹤0.01% of the portfolio, ranked #4290.

Tower Research Capital (TRC) first reported a position in BIAF in Q3 2022 and has held it in 14 quarters since. The position peaked at $9.97K in Q2 2024. 14 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

  • Tower Research Capital (TRC) held 6,482 shares of bioAffinity Technologies worth $5.26K as of Q2 2026.
  • Tower Research Capital (TRC) bought 4,419 bioAffinity Technologies shares in Q2 2026, an estimated $9.03K.
  • bioAffinity Technologies made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4290 holding.
  • Tower Research Capital (TRC) first reported a position in bioAffinity Technologies in Q3 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s bioAffinity Technologies position peaked at $9.97K in Q2 2024.
  • 14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.